Takeda positive on norovirus vaccine despite missed endpoint
This article was originally published in Scrip
Executive Summary
Takeda appears ready to press ahead with the development of its first-in-class candidate vaccine for norovirus, saying it is encouraged by an early clinical trial with the bivalent product despite the challenge study missing its primary endpoint.